We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » Real World Evidence and Data – Webinar Recording/Transcript

Other Options

USB Audio Recording/Transcript - Aug. 15, 2019

$287.00

USB Audio Recording/Transcript - Aug. 15, 2019

$258.00

USB Audio Recording/Transcript - Aug. 15, 2019

$244.00

USB Audio Recording/Transcript - Aug. 15, 2019

$230.00

USB Audio Recording/Transcript - Aug. 15, 2019

$215.00

Real World Evidence and Data – Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

Real World Evidence and Data: A Tufts Study of 30 Pharma Companies

Real world evidence (RWE) is making its way into your world.

Some bold drugmakers are finding ways to take business advantage of the opportunities RWE offers, while others hang back, worried about risks and unforeseen consequences.

The Tufts Center for the Study of Drug Development (CSDD) investigated how the industry is using real world data (RWD) and RWE. The study of 30 biopharmaceutical companies includes current and planned used of RWD, operational issues and return on investment and performance areas impacted by RWE.

Presentation Takeaways:

Based on their knowledge, and using several recent case studies, Dr. Mary Jo Lamberti — associate director of sponsored research at the CSDD — and Francis Kendall — senior director at Cytel — will share valuable information on:

  • Types of technology used to access or collect RWD and evidence and partnerships that support usage
  • Significant challenges to using RWD as well as strategies and practices that impact return on investment or performance
  • The key drivers for change and the adoption of RWE
  • The potential of RWE and how it may be used across the clinical development pipeline
  • A view on what will happen next in the RWE domain

Understand the critical factors you need to consider in using RWE and gain insight into the current and planned uses of RWE to support development and post-approval safety studies.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing